We are thrilled to announce that myNEO Therapeutics has partnered with the University of Liverpool to launch a groundbreaking Phase 1 clinical trial focused on developing a personalised therapeutic cancer vaccine for patients with Non-Small Cell Lung Cancer (NSCLC).
This collaboration represents a step forward in the fight against cancer, utilizing our cutting-edge ImmunoEngine technology to identify patient-specific neoantigens. By tailoring the vaccine to each patient’s unique tumour profile, we aim to enhance the immune system’s ability to target and eliminate cancer cells, with the goal of improving treatment outcomes for NSCLC patients.